Provided by Tiger Trade Technology Pte. Ltd.

AKESO

88.850
-1.050-1.17%
Volume:1.48M
Turnover:131.63M
Market Cap:81.83B
PE:-61.78
High:90.300
Open:89.900
Low:87.900
Close:89.900
52wk High:159.800
52wk Low:80.200
Shares:921.00M
HK Float Shares:921.00M
Volume Ratio:1.90
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.438
ROE:-13.59%
ROA:-4.57%
PB:8.27
PE(LYR):-61.78
PS:20.33

Loading ...

HK Biotech Stocks Fell. Akeso Down 12%; Remegen, Zai Lab, KeyMed And Junshi Down 7%; Lepu And Innocare Down 6%

Tiger Newspress
·
Apr 23

Stock Track | AKESO Plummets 5.69% Intraday as Fundamental Concerns Overshadow Positive Clinical Data

Stock Track
·
Apr 23

Is It Too Late To Consider Akeso (SEHK:9926) After Strong Five Year Share Gains?

Simply Wall St.
·
Apr 22

AKESO Shares Climb Nearly 3% on Positive Phase II Data for Cadonilimab Combo in Pancreatic Cancer

Stock News
·
Apr 22

Akeso says cadonilimab-chemo extends OS past 23 months in phase 2 pancreatic cancer trial

Reuters
·
Apr 21

China International Capital Corporation: National Policy Optimizes Initial Pricing Mechanism for Innovative Drugs, Pharmaceutical Sector Set for High-Quality Development

Stock News
·
Apr 16

Stock Track | Akeso Soars 5.08% Intraday on Strong Earnings and Sector Momentum

Stock Track
·
Apr 15

Assessing Akeso (SEHK:9926) Valuation After Positive Lung Cancer Data At 2026 European Lung Cancer Congress

Simply Wall St.
·
Apr 13

AKESO Keeps Share Count Steady at 921.14 Million in March, Confirms Public Float Compliance

Bulletin Express
·
Apr 08

Guojin Securities Maintains "Buy" Rating on AKESO (09926) as Clinical Trials Progress

Stock News
·
Apr 07

Akeso says cadonilimab combo posts 7-month median PFS in resistant NSCLC study

Reuters
·
Apr 07

Akeso (SEHK:9926) Valuation Check After New HARMONi-2 Quality Of Life And Survival Data

Simply Wall St.
·
Apr 06

China International Capital Corp. Highlights Positive Trends in Domestic Innovative Drug Sector, Anticipates Key Academic Developments in 2026

Stock News
·
Apr 03

Stock Track | AKESO Soars 5.53% Intraday on Positive Phase III Quality-of-Life Results for Ivonescimab

Stock Track
·
Apr 01

Akeso says ivonescimab improves quality of life vs pembrolizumab in Phase III NSCLC study

Reuters
·
Apr 01

Mainland Investors Divest HK$2.47 Billion from Hong Kong Market, Offloading ETFs and Oil Stocks While Boosting Tencent Holdings

Stock News
·
Mar 30

Akeso (SEHK:9926) FY 2025 Loss Deepens Despite 2H Revenue Growth Challenging Bullish Narratives

Simply Wall St.
·
Mar 28

Akeso Widens Loss in 2025; Shares Climb 3%

MT Newswires Live
·
Mar 27

Press Release: Akeso Reports Full-Year 2025 Financial Results

Dow Jones
·
Mar 27

Stock Track | AKESO Plummets 5.42% Intraday as FY2025 Loss Widens to CNY 1.1 Billion Despite Revenue Growth

Stock Track
·
Mar 27